Group 1 - The core viewpoint of the article is that Green Tea Group (06831) has announced a positive profit forecast, leading to a stock price increase of over 6% [1] - The company expects a profit of approximately 230 million to 237 million RMB for the six months ending June 30, 2025, representing a year-on-year increase of about 32% to 36% [1] - The adjusted net profit is anticipated to be around 247 million to 254 million RMB, reflecting a year-on-year increase of approximately 38% to 42% [1] Group 2 - The profit increase is primarily attributed to the continuous expansion of the company's store network, which is expected to boost revenue from approximately 1.86 billion RMB last year to an increase of about 391 million to 465 million RMB [1] - The improvement in operational efficiency has led to enhanced profitability at the store level, although this has been partially offset by expenses related to the company's public listing during the period [1] - The growth in adjusted net profit is also driven by the expansion of the store network and the ongoing enhancement of operational efficiency [1]

绿茶集团表示，利润增加主要是由于以下各项的综合影响，包括集团的门店网络持续扩张导致收入较截 至2024年6月30日止六个月的约18.60亿元增加约3.91亿元至4.65亿元。同时，经营效率的持续提升导致 门店层面盈利能力提高，以及部分被截至2025年6月30日止六个月产生的上市开支(约1500万元至2000万 元)所抵销。经调整净利润增加主要由于以下各项的综合影响，包括集团的门店网络持续扩张导致上述 收入增加，以及经营效率的持续提升导致门店层面盈利能力提高。 北京商报讯（记者 张天元）7月31日，绿茶集团发布盈利预告，其中显示，集团预期2025年上半年利润 约2.30亿元(人民币，下同)至2.37亿元，而上年同期约为1.74亿元，增加约32%至36%;上半年经调整净利 润约2.47亿元至2.54亿元，上年同期约为1.79亿元，增加约38%至42%。 ...

Performance Updates - 开拓药业-B (09939.HK) has completed patient enrollment for the Phase III clinical trial of KX-826 solution for androgenetic alopecia in adult males in China [2] - 李氏大药厂 (00950.HK) has received approval from the National Medical Products Administration for Socazolimab to be used in combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer in mainland China [2] - 恒瑞医药 (01276.HK) has received approval for clinical trials of SHR-8068 injection, Adebali monoclonal antibody injection, and Bevacizumab injection [2] - 恒瑞医药 (01276.HK) has also received approval to conduct clinical trials for HRS-5041, intended for prostate cancer treatment [2] - 深圳高速公路股份 (00548.HK) reported toll revenue of 106 million yuan for the outer ring project in June [2] - 大成生化科技 (00809.HK) has signed an EPC contract with Northeast Electric and Liaoning Electric for boiler renovation projects, with a maximum cost of 129.1 million yuan [2] - 小黄鸭德盈 (02250.HK) has signed a contract to develop an AI marketing system to diversify revenue sources [2] Buyback and Financing Activities - 威海银行 (09677.HK) plans to issue up to approximately 758 million domestic shares and 154 million H-shares, raising nearly 3 billion yuan [2] Financial Results - 香港电讯-SS (06823.HK) reported total revenue of 17.322 billion HKD for the first half, a year-on-year increase of 4%, with a net profit of 2.07 billion HKD, also up 4% [4] - 青岛银行 (03866.HK) reported operating revenue of 7.662 billion yuan for the first half, a growth of 7.5%, and a net profit of 3.065 billion yuan, up 16.05% [4] - 中国石油化工股份 (00386.HK) expects mid-term net profit to be between 20.1 billion and 21.6 billion yuan, a year-on-year decline of 39.5%-43.7% [4] - 汽车之家-S (02518.HK) reported total revenue of 3.212 billion yuan for the first half, a decrease of 7.75%, with a net profit of 772 million yuan, down 15.99% [4] - 绿茶集团 (06831.HK) issued a profit warning, expecting mid-term net profit to be between 230 million and 237 million yuan, a year-on-year increase of approximately 32%-36% [4] - 粤海置地 (00124.HK) issued a profit warning, expecting mid-term net profit to exceed 260 million HKD, turning from loss to profit [4] - 药师帮 (09885.HK) issued a profit warning, expecting mid-term net profit to exceed 70 million yuan [4] - 中国东方教育 (00667.HK) issued a profit warning, expecting mid-term net profit to grow by 45%-50% year-on-year [4] - 中核国际 (02302.HK) issued a profit warning, expecting mid-term revenue to increase to at least 585 million HKD, with net profit of at least 9.5 million HKD [4] - 大唐环境 (01272.HK) issued a profit warning, expecting mid-term net profit to decrease to between 350 million and 400 million yuan [4] - 长江生命科技 (00775.HK) issued a profit warning, expecting mid-term net loss of approximately 150 million HKD, turning from profit to loss year-on-year [4] - 延长石油国际 (00346.HK) issued a profit warning, expecting mid-term loss of approximately 27.9 million HKD [4]

董事会谨此强调，国际财务报告准则会计准则并无对"经调整净利润"作出界定。集团对经调整净利润定 义为透过剔除(i)以权益结算的股份支付开支、(ii)上市开支及(iii)与上述(i)至(ii)项相关的税项影响而作出 调整的期内利润。 董事会认为，"经调整净利润"将通过消除非营运性或一次性性质且不表明集团实际营运表现的经调整项 目的潜在影响，向潜在投资者及其他人士就了解及评估集团经营业绩提供有用资料。尤其是，以权益结 算的股份支付开支为公司于2020年2月28日采纳的受限制股份单位计划产生的非现金开支。 格隆汇7月31日丨绿茶集团(06831.HK)发布正面盈利预告，基于对集团截至2025年6月30日止6个月的未 经审核综合管理账目的初步审阅以及董事会目前可得的资料，预期集团将录得(i)截至2025年6月30日止6 个月的利润约人民币2.3亿元至人民币2.37亿元，而截至2024年6月30日止6个月则约为人民币1.74亿元， 增加约32%至36%；及(ii)截至2025年6月30日止6个月的经调整净利润约人民币2.47亿元至人民币2.54亿 元，而截至2024年6月30日止6个月则约为人民币1.79亿元，增加约38 ...

智通财经APP讯，绿茶集团(06831)发布公告，预期集团将取得(i)截至2025年6月30日止六个月的利润约 2.30亿元(人民币，下同)至2.37亿元，而截至2024年6月30日止六个月则约为1.74亿元，增加约32%至 36%;及(ii)截至2025年6月30日止六个月的经调整净利润约2.47亿元至2.54亿元，而截至2024年6月30日止 六个月则约为1.79亿元，增加约38%至42%。 公告称，(1)利润增加乃主要由于以下各项的综合影响：(i)集团的门店网络持续扩张导致收入较截至 2024年6月30日止六个月的约18.60亿元增加约3.91亿元至4.65亿元;(ii)经营效率的持续提升导致门店层面 盈利能力提高;及(iii)部分被截至2025年6月30日止六个月产生的上市开支(约1500万元至2000万元)所抵 销;及 (2)经调整净利润增加乃主要由于以下各项的综合影响：(i)集团的门店网络持续扩张导致上述收入增加; 及(ii)经营效率的持续提升导致门店层面盈利能力提高。 ...

公告称，(1)利润增加乃主要由于以下各项的综合影响：(i)集团的门店网络持续扩张导致收入较截至 2024年6月30日止六个月的约18.60亿元增加约3.91亿元至4.65亿元;(ii)经营效率的持续提升导致门店层面 盈利能力提高;及(iii)部分被截至2025年6月30日止六个月产生的上市开支(约1500万元至2000万元)所抵 销;及 (2)经调整净利润增加乃主要由于以下各项的综合影响：(i)集团的门店网络持续扩张导致上述收入增加; 及(ii)经营效率的持续提升导致门店层面盈利能力提高。 绿茶集团(06831)发布公告，预期集团将取得(i)截至2025年6月30日止六个月的利润约2.30亿元(人民币， 下同)至2.37亿元，而截至2024年6月30日止六个月则约为1.74亿元，增加约32%至36%;及(ii)截至2025年6 月30日止六个月的经调整净利润约2.47亿元至2.54亿元，而截至2024年6月30日止六个月则约为1.79亿 元，增加约38%至42%。 ...

Core Viewpoint - Green Tea Group expects a significant increase in net profit for the first half of the fiscal year ending June 30, 2025, with an estimated growth of approximately 32% to 36% compared to the same period in 2024 [1] Financial Performance - The company anticipates net profit to be between RMB 230 million and RMB 237 million for the six months ending June 30, 2025, compared to approximately RMB 174 million for the same period in 2024 [1] - Adjusted net profit is projected to range from RMB 247 million to RMB 254 million for the first half of 2025, representing an increase of about 38% to 42% from approximately RMB 179 million in the first half of 2024 [1]

Green Tea Group Limited 綠茶集團有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6831） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 正面盈利預告 本公告乃由綠茶集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章 《證券及期貨條例》第XIVA部內幕消息條文（定義見上市規則）作出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，基於對 本集團截至2025年6月30日止六個月的未經審核綜合管理賬目的初步審閱以及董 事會目前可得的資料，預期本集團將錄得(i)截至2025年6月30日止六個月的利潤 介乎約人民幣230百萬元至人民幣237百萬元，而截至2024年6月30日止六個月則 約為人民幣174百萬元，增加約32%至36%；及(ii)截至2025年6月30日止六個月 的經調整淨利潤介乎約人民幣247百 ...

Company Overview - The company is a well-known operator of Chinese casual dining restaurants, positioned in the value-for-money and high-quality environment segment of the Chinese fusion cuisine market [1] - As of May 2025, the company operates 493 stores through a direct-operated model, covering Hong Kong and various cities in mainland China [1] - The company's existing stores maintain healthy operations, with 2024 sales per old store expected to exceed 10 million yuan [1] Industry Analysis - The restaurant industry in China is projected to reach a market size of 5.6 trillion yuan in 2024, with chain restaurants accounting for 23.3% of revenue, an increase of 4.2 percentage points since 2019 [2] - The company ranks fourth in the market with a projected revenue of 3.8 billion yuan in 2024, achieving a market share of 0.7% [2] - The industry is experiencing a shift towards affordable and online dining options, with online ordering expected to account for 28% of total orders in 2024 [2] Competitive Advantages - The company has strong research and development capabilities, with the founder serving as the "product manager" to lead menu development [2] - Existing stores maintain an average annual sales of over 10 million yuan, and the investment payback period for new stores has been reduced to 14-15 months due to smaller and more efficient store models [2] - The company is implementing a store profit-sharing mechanism to incentivize core employees and ensure high-quality operations and expansion [2] Investment Outlook - Revenue projections for the company are 4.68 billion yuan in 2025, 5.90 billion yuan in 2026, and 7.50 billion yuan in 2027, with year-on-year growth rates of 22.0%, 25.9%, and 27.3% respectively [3] - Adjusted net profits are expected to be 490 million yuan in 2025, 590 million yuan in 2026, and 750 million yuan in 2027, with growth rates of 34.8%, 22.1%, and 25.9% respectively [3] - The company is rated as a "buy" based on its accelerated store expansion and improved single-store efficiency [3]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [6][15][19]. Core Insights - The company is a well-known operator of Chinese casual dining restaurants, focusing on cost-effectiveness and high-quality dining experiences. As of May 2025, it operates 493 stores across Hong Kong and various cities in mainland China [4][12][17]. - The company’s mature stores maintain healthy operations, with projected sales for 2024 expected to exceed 10 million yuan per store. The increase in takeaway orders is anticipated to help same-store sales recover [4][12][17]. - The company has recently experimented with smaller restaurant formats, which have higher table turnover rates and lower operating costs, leading to a reduced payback period of 14-15 months for new stores. With effective incentive mechanisms in place, the company is expected to accelerate its store expansion [4][12][17]. Summary by Sections Company Overview - The company started from Hangzhou West Lake and has expanded nationwide, opening its first restaurant in 2008. By May 2025, it has established a network of 493 restaurants across various city tiers in China [23]. - The main business model is direct-operated restaurants with a focus on fusion cuisine priced between 50-70 yuan, achieving a competitive edge through high cost-performance [25][26]. Industry Analysis - The Chinese restaurant market is projected to reach 5.6 trillion yuan in 2024, with a compound annual growth rate (CAGR) of 3.6% from 2019 to 2024. The casual dining segment is the fastest-growing within the Chinese restaurant market, with a CAGR of 5.6% [49][53]. - The chain restaurant penetration rate in China has increased to 23.3% in 2024, up 4.2 percentage points from 2019, indicating a gradual shift towards more standardized and scalable restaurant operations [55]. Competitive Advantages - The company boasts strong menu development capabilities, with its founder leading product innovation. The average annual sales for mature stores remain above 10 million yuan, and the investment payback period for new stores has decreased due to smaller, more efficient formats [14][19]. - The company has implemented a profit-sharing mechanism to align employee interests with operational quality and expansion goals, enhancing its competitive position [14][19]. Growth Outlook - Revenue is expected to grow significantly, with projections of 46.8 billion yuan in 2025, 59.0 billion yuan in 2026, and 75.0 billion yuan in 2027, reflecting year-on-year growth rates of 22.0%, 25.9%, and 27.3% respectively [15][19]. - The company plans to open 131, 176, and 183 new stores in 2025, 2026, and 2027, respectively, supported by a favorable market environment and improved operational efficiencies [18][19].